T2D PT201
Alternative Names: T1D-PT201Latest Information Update: 11 Mar 2024
At a glance
- Originator Porosome Therapeutics
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 27 Feb 2024 Preclinical trials in Type 2 diabetes mellitus in USA (unspecified route) Porosome Therapeutics pipeline, February 2024)